Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOVIE INC.BIVI · Entity 7702 | EVP Neuroscience R&D | February 16, 2023 | February 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOVIE INC.
Report date February 16, 2023 · Filed February 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 37,148 |
Reported balance
After 2023-02-16 transaction · row 1
1 source rowRow 1 · 2023-02-16 · Tax withholding · Disposed 2,476 · Balance 37,148 F1: Transaction code F - Payment of tax liability by withholding securities incident to the receipt |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction code F - Payment of tax liability by withholding securities incident to the receipt
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2023 Filed Feb 22, 2023 17:47 UTC | BIOVIE INC. BIVI · Entity 7702 | Tax withholdingCOMMON STOCK | 2,476 | $6.12 | $15,153.12 |
DisclosureSEC source: 0001520138-23-000110 · ownership.xml · nonDerivative · entry 1 READING CHRISTOPHER · CIK 0001239658 · EVP Neuroscience R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,148 F1 · kind: Transaction code F - Payment of tax liability by withholding securities incident to the receipt Read SEC document |
| November 23, 2022 Filed Jan 18, 2023 16:24 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCOMMON STOCK | 39,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-23-000058 · ownership.xml · nonDerivative · entry 1 READING CHRISTOPHER · CIK 0001239658 · EVP Neuroscience R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,624 Read SEC document |
| August 20, 2021 Filed Oct 8, 2021 14:59 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 124,167 | $0.00 Strike: $7.74 | $0.00 |
DisclosureSEC source: 0001520138-21-000612 · ownership.xml · derivative · entry 1 READING CHRISTOPHER · CIK 0001239658 · EVP Neuroscience R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,167 Underlying: Common Stock · 124,167 shares Expires 2031-08-19 F1 · derivative.exercise_date: This option was 20% vested upon grant, with an additional 16% on each of the first five anniversaries of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.